Sex Transm Infect 89:133-137 doi:10.1136/sextrans-2012-050486
  • Epidemiology
  • Original article

Cross-sectional study on the prevalence of HPV antibodies in the general population of the Czech Republic

Open Access
  1. Ruth Tachezy
  1. Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Praha 2, Czech Republic
  1. Correspondence to Dr Eva Hamsikova, Department of Experimental Virology, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20 Praha 2, Czech Republic; eva.hamsikova{at}
  1. Contributors EH participated in the design and coordination of the study, evaluated results, performed statistical analysis and drafted the manuscript. VL prepared antigens for assessment of antibody presence. JS performed the immunoassays. RT participated in the design of the study and helped to draft the manuscript. All authors read and approved the final manuscript.

  • Accepted 9 May 2012
  • Published Online First 8 June 2012


Objectives The assessment of the prevalence of antibodies to human papillomaviruses (HPV) in the healthy population is essential for effective planning of HPV vaccine implementation into the preventive programmes for HPV-associated diseases and for the prospective monitoring of the impact of HPV vaccines in the Czech population.

Methods The seropositivity for HPV-6, 11, 16, 18, 31 and 33 virus-like particles was determined in sera from 3150 healthy individuals (age range 6–76 years) by means of enzyme-linked immunoassay.

Results The seroprevalences for HPV-6, 11, 16, 18, 31 and 33 were 23.8%, 15.2%, 14.5%, 9.9%, 16.4% and 9.6% in women and 18.4%, 13.7%, 6.5%, 5.4%, 6.1% and 4.3% in men. For both genders, except for HPV11, these rates were age dependent. The prevalence of antibodies to HPV-16 and/or 18 reached the maximum of 27.0% in women 30–39 years of age and of 14.4% in men 50–59 years of age. The highest proportion of individuals' seropositive for any of the vaccine types HPV-6/11/16/18 was in 30- to 39-year-old women (50.0%) and in ≥60-year-old men (37.6%). Antibodies specific for vaccine HPV types were detected in 18.0% of children 6- to 14-year-old but in 26.4%, those older than 14 years.

Conclusions The data reveal age-specific differences in the HPV seropositivity rates between healthy women and men and support the implementation of HPV vaccination in the Czech Republic before the age of 13.


  • Funding The work was funded by the Internal Grant Agency of the Ministry of Health of the Czech Republic, grants Nos. NS/9984 and NT/12372. The funder provided financial support for this project. The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

  • Competing interests RT is a member of the Czech GSK advisory board; the other authors have no conflicts of interest.

  • Patient consent Serum samples were derived from serological surveys performed in the Czech Republic by the National Institute of Public Health aimed to provide information about the immunity status of the population and basic data for decision on potential changes in the vaccination strategies. Such surveys have been carried out in the Czech Republic since 1971. Persons enrolled in the survey were randomly selected in cooperation with regional and district sanitary offices and with practitioners for adults, adolescents and children. Blood samples were collected in various urban and rural populations from healthy individuals 6–64 years of age. The blood samples were taken from subjects with no acute febrile disease and no signs of immunodeficiency on the day of sampling. All enrolled subjects signed informed consent, in case of children, the informed consent was signed by parents. The blood sample was coded with regard to region, district, physician and client. All sera were aliquoted, registered in the Serum Bank of the Centre for Epidemiology and Microbiology, National Institute of Public Health, and kept frozen. The set of samples analysed in our study comprised of sera collected in the year 1996 and 2001. For the purpose of our study, all sera were marked by laboratory ID and no identification of particular person was possible. In addition, we included sera from anonymous blood donors sampled in the period of 1999–2005. All blood donors sign information consent form under the blood sampling. Those samples are mandatory tested for the presence of markers of infections transmitted by blood and discarded.

  • Ethics approval The study was approved by the Ethics committee of Institute of Hematology and Blood Transfusion (#EK 2IGA/9/2009).

  • Provenance and peer review Not commissioned; externally peer reviewed.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: and